<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418002</url>
  </required_header>
  <id_info>
    <org_study_id>CAQW051A2102</org_study_id>
    <nct_id>NCT00418002</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.</brief_title>
  <official_title>A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and tolerability of AQW051 administered in
      single and multiple doses to elderly healthy volunteers. In addition, pharmacokinetic effects
      will be assessed and the possible effects on cognition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics at the end of the study.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess a potential food effect on pharmacokinetics of AQW051.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the drug abuse liability potential of AQW051.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQW051</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and postmenopausal female subjects between 60 to 80 years of age and in
             good health as determined by past medical history.

          -  Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior
             to inclusion.

          -  Male subjects must be using a double-barrier local contraception.

          -  Body mass index must be within the range of 18 to 33. Subjects must weigh at least 50
             kg to participate in this study.

          -  The regular intake of concomitant drugs including thyroxine, paracetamol, low dose
             non-steroidal anti-inflammatory drugs, lipid lowering drugs, vitamins and dietary
             supplements without caffeine and nicotinic acid, and hormone replacement therapy is
             allowed, if on stable treatment for at least 3 months. Intake of nutritional
             supplements (e.g. omega-3, vitamins, minerals, cod-liver oil) is allowed.

          -  Able to communicate well with the investigator, to understand and comply with the
             requirements of the study. Understand and sign the written informed consent.

        Exclusion Criteria:

          -  Smokers (use of tobacco products in the previous 3 months).

          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter
             medication (e.g. herbal supplements) within 2 weeks prior to study start except noted
             previously

          -  Use of any central nervous system active drug and anticholinergic drugs during the
             previous 3 months and use of any drug or treatment known to cause major organ system
             toxicity during the previous 3 months is prohibited.

          -  A past personal or close family medical history of clinically significant cardiac
             abnormalities.

          -  Current diagnosis of cardiac arrhythmia derived from ECG and/or Holter ECG.

          -  Current diagnosis of cardiovascular disease.

          -  Current diagnosis or history of autonomic dysfunction (e.g. history of fainting,
             orthostatic hypotension, sinus arrhythmia).

          -  History of Acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease) Clinically significant drug allergy or history of
             atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or
             severe adverse event to darifenacin or similar drugs Any surgical or medical condition
             which might significantly alter the absorption, distribution, metabolism or excretion
             of drugs or which may jeopardize participation in the study Immunodeficiency diseases,
             including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B
             surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse within the
             12 months prior to dosing.

          -  Diagnosis of cognitive impairment (Mini Mental State Exam &lt; 27).

          -  History or current diagnosis of a cerebrovascular disease (e.g., stroke, transient
             ischemic attacks, aneurysms).

          -  Current DSM-IV diagnosis of major depression and/or any other DSM-IV Axis 1 diagnosis
             that may interfere with the evaluation of the patientâ€™s response to study medication,
             including other primary neurodegenerative dementia, schizophrenia, or bipolar
             disorder.

          -  History or current diagnosis of an active, uncontrolled seizure disorder.

          -  History of head injury or any other neurological disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Horsham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.</keyword>
  <keyword>Healthy elderly male and female subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

